Forest COPD Combo Hits Roadblock En Route To NDA Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.